A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer

The association between genetic variations and immunotherapy benefit has been widely recognized, while such evidence in gastrointestinal cancer remains limited. We analyzed the genomic profile of 227 immunotherapeutic gastrointestinal cancer patients treated with immunotherapy, from the Memorial Slo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Xi, Wei, Xin, Li, Shuang, Liu, Chang, Chen, Huan, Gong, Jifang, Li, Jian, Zhang, Xiaotian, Wang, Xicheng, Peng, Zhi, Qi, Changsong, Wang, Zhenghang, Wang, Yujiao, Wang, Yanni, Zhuo, Na, Zhang, Henghui, Lu, Zhihao, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096820/
https://www.ncbi.nlm.nih.gov/pubmed/33947957
http://dx.doi.org/10.1038/s41698-021-00172-5
_version_ 1783688224299810816
author Jiao, Xi
Wei, Xin
Li, Shuang
Liu, Chang
Chen, Huan
Gong, Jifang
Li, Jian
Zhang, Xiaotian
Wang, Xicheng
Peng, Zhi
Qi, Changsong
Wang, Zhenghang
Wang, Yujiao
Wang, Yanni
Zhuo, Na
Zhang, Henghui
Lu, Zhihao
Shen, Lin
author_facet Jiao, Xi
Wei, Xin
Li, Shuang
Liu, Chang
Chen, Huan
Gong, Jifang
Li, Jian
Zhang, Xiaotian
Wang, Xicheng
Peng, Zhi
Qi, Changsong
Wang, Zhenghang
Wang, Yujiao
Wang, Yanni
Zhuo, Na
Zhang, Henghui
Lu, Zhihao
Shen, Lin
author_sort Jiao, Xi
collection PubMed
description The association between genetic variations and immunotherapy benefit has been widely recognized, while such evidence in gastrointestinal cancer remains limited. We analyzed the genomic profile of 227 immunotherapeutic gastrointestinal cancer patients treated with immunotherapy, from the Memorial Sloan Kettering (MSK) Cancer Center cohort. A gastrointestinal immune prognostic signature (GIPS) was constructed using LASSO Cox regression. Based on this signature, patients were classified into two subgroups with distinctive prognoses (p < 0.001). The prognostic value of the GIPS was consistently validated in the Janjigian and Pender cohort (N = 54) and Peking University Cancer Hospital cohort (N = 92). Multivariate analysis revealed that the GIPS was an independent prognostic biomarker. Notably, the GIPS-high tumor was indicative of a T-cell-inflamed phenotype and immune activation. The findings demonstrated that GIPS was a powerful predictor of immunotherapeutic survival in gastrointestinal cancer and may serve as a potential biomarker guiding immunotherapy treatment decisions.
format Online
Article
Text
id pubmed-8096820
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80968202021-05-05 A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer Jiao, Xi Wei, Xin Li, Shuang Liu, Chang Chen, Huan Gong, Jifang Li, Jian Zhang, Xiaotian Wang, Xicheng Peng, Zhi Qi, Changsong Wang, Zhenghang Wang, Yujiao Wang, Yanni Zhuo, Na Zhang, Henghui Lu, Zhihao Shen, Lin NPJ Precis Oncol Article The association between genetic variations and immunotherapy benefit has been widely recognized, while such evidence in gastrointestinal cancer remains limited. We analyzed the genomic profile of 227 immunotherapeutic gastrointestinal cancer patients treated with immunotherapy, from the Memorial Sloan Kettering (MSK) Cancer Center cohort. A gastrointestinal immune prognostic signature (GIPS) was constructed using LASSO Cox regression. Based on this signature, patients were classified into two subgroups with distinctive prognoses (p < 0.001). The prognostic value of the GIPS was consistently validated in the Janjigian and Pender cohort (N = 54) and Peking University Cancer Hospital cohort (N = 92). Multivariate analysis revealed that the GIPS was an independent prognostic biomarker. Notably, the GIPS-high tumor was indicative of a T-cell-inflamed phenotype and immune activation. The findings demonstrated that GIPS was a powerful predictor of immunotherapeutic survival in gastrointestinal cancer and may serve as a potential biomarker guiding immunotherapy treatment decisions. Nature Publishing Group UK 2021-05-04 /pmc/articles/PMC8096820/ /pubmed/33947957 http://dx.doi.org/10.1038/s41698-021-00172-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Jiao, Xi
Wei, Xin
Li, Shuang
Liu, Chang
Chen, Huan
Gong, Jifang
Li, Jian
Zhang, Xiaotian
Wang, Xicheng
Peng, Zhi
Qi, Changsong
Wang, Zhenghang
Wang, Yujiao
Wang, Yanni
Zhuo, Na
Zhang, Henghui
Lu, Zhihao
Shen, Lin
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
title A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
title_full A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
title_fullStr A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
title_full_unstemmed A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
title_short A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
title_sort genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096820/
https://www.ncbi.nlm.nih.gov/pubmed/33947957
http://dx.doi.org/10.1038/s41698-021-00172-5
work_keys_str_mv AT jiaoxi agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT weixin agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT lishuang agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT liuchang agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT chenhuan agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT gongjifang agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT lijian agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT zhangxiaotian agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT wangxicheng agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT pengzhi agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT qichangsong agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT wangzhenghang agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT wangyujiao agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT wangyanni agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT zhuona agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT zhanghenghui agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT luzhihao agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT shenlin agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT jiaoxi genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT weixin genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT lishuang genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT liuchang genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT chenhuan genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT gongjifang genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT lijian genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT zhangxiaotian genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT wangxicheng genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT pengzhi genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT qichangsong genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT wangzhenghang genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT wangyujiao genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT wangyanni genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT zhuona genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT zhanghenghui genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT luzhihao genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer
AT shenlin genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer

Ejemplares similares